Product Name

Crizotinib

General description

Crizotinib is an orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity.

Synonym

(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; (R)-crizotinib; PF-2341066; PF-02341066

Purity

≥98%(HPLC)

CAS Number

877399-52-5

Formula

C²¹H²²Cl²FN⁵O

Molecular Weight

450.34

Suitability

BioReagent, suitable for cell culture, etc.

l  Physical and Chemical Information

Appearance

Yellow white solid

Solubility(25℃)

DMSO

~9mg/mL

Ethanol

Insoluble

Water

Insoluble

l  Biological Information

Biochem/Physiol   Actions

Crizotinib is an orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.

Application

Protein Kinase Inhibitors

l  Packaging & Storage

Packaging

25mg; 100mg; 250mg

Storage temp.

-20℃

l  Precautions and Disclaimer

This   product is for R&D use only, not for drug, household, or other uses.

l  References

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.    https://www.ncbi.nlm.nih.gov